A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR

James M. Cleary, Emiliano Calvo, Víctor Moreno, Dejan Juric, Geoffrey I. Shapiro, Carol Ann Vanderwal, Beibei Hu, Maryella Gifford, David Barch, Lisa Roberts-Rapp,

Investigational New Drugs · 2020 · 31 citations · 16 references

Concepts

References

16